RT Journal Article
SR Electronic
T1 Predictive value of automated coronary calcium scoring in lung cancer screening with low dose computed tomography
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.13.22276338
DO 10.1101/2022.06.13.22276338
A1 Sabia, Federica
A1 Balbi, Maurizio
A1 Ledda, Roberta E.
A1 Milanese, Gianluca
A1 Ruggirello, Margherita
A1 Valsecchi, Camilla
A1 Marchianò, Alfonso
A1 Sverzellati, Nicola
A1 Pastorino, Ugo
YR 2022
UL http://medrxiv.org/content/early/2022/06/13/2022.06.13.22276338.abstract
AB Coronary artery calcium (CAC) is a known risk factor for cardiovascular events, but not yet routinely evaluated in Low Dose Computed Tomography (LDCT) screening. The present analysis compared the accuracy of a new automated CAC quantification versus prior manual quantification on baseline LDCT screening images as predictors of all-cause mortality at 12 years.The study included 1129 volunteers of the Multicentric Italian Lung Detection (MILD) trial who underwent a baseline LDCT scan from September 2005 to September 2006, already analyzed in a previous paper on CAC scoring. The initial manual CAC (mCAC) had been scored by one operator using a dedicated software, while the new automated CAC (aCAC) score was measured by a fully automated artificial intelligence software. All CAC scores were stratified in four categories: 0, 0.1- 19.9, 20-399, and ≥ 400.The study showed a high correlation between aCAC and mCAC scores, with an Intraclass Correlation Coefficient of 0.887. Of 613 negative mCAC score, 87.6% had aCAC score >0, and 14.0% >20. A CAC score >20 revealed a higher risk of 12-year all-cause mortality both with mCAC and aCAC. Focusing on the 535 individuals with false negative mCAC score, aCAC identified a subset of volunteers with a significantly poorer survival of 86% (aCAC 20-399, p=0.0007).CAC quantification could be accurately and safely performed with a fully automated software on baseline LDCT screening images to predict all-cause mortality risk.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02837809Clinical Protocols https://www.clinicaltrials.gov/ct2/show/NCT02837809?term=NCT02837809&draw=2&rank=1 Funding StatementThe MILD trial was supported by grants from the Italian Ministry of Health (RF 2004), the Italian Association for Cancer Research (AIRC 2004 IG 1227 and AIRC 5xmille IG 12162), Fondazione Cariplo (2004-1560), and the National Cancer Institute (EDRN UO1 CA166905). The sponsors had no role in conducting and interpreting the study. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board and the Ethics Committee of the Fondazione IRCCS Istituto Nazionale dei Tumori of Milan approved the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors